Display options
Cite
Bjur KA, Cannon BC, Fine AL, et al. Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus. Case Rep Pediatr. 2017;2017:2979486doi: 10.1155/2017/2979486.
Bjur, K. A., Cannon, B. C., Fine, A. L., Ritter, M. J., Schueler, K. E., & Nemergut, M. E. (2017). Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus. Case reports in pediatrics, 20172979486. https://doi.org/10.1155/2017/2979486
Bjur, Kara A, et al. "Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus." Case reports in pediatrics vol. 2017 (2017): 2979486. doi: https://doi.org/10.1155/2017/2979486
Bjur KA, Cannon BC, Fine AL, Ritter MJ, Schueler KE, Nemergut ME. Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus. Case Rep Pediatr. 2017;2017:2979486. doi: 10.1155/2017/2979486. Epub 2017 Feb 26. PMID: 28331645; PMCID: PMC5346383.
Copy Download .nbib Format: NLM
Share it on

Case Rep Pediatr. 2017;2017:2979486. doi: 10.1155/2017/2979486. Epub 2017 Feb 26.

Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus.

Case reports in pediatrics

Kara A Bjur, Bryan C Cannon, Anthony L Fine, Matthew J Ritter, Kerry E Schueler, Michael E Nemergut

Affiliations

  1. Mayo Clinic, Rochester, MN, USA.

PMID: 28331645 PMCID: PMC5346383 DOI: 10.1155/2017/2979486

Abstract

Propylene glycol (PG) is a solvent commonly used in medications that, while benign at low doses, may cause toxicity in adults and children at high doses. We describe a case and the physiologic sequelae of propylene glycol toxicity manifested in a critically ill adolescent male with refractory myoclonic status epilepticus aggressively treated with multiple PG-containing medications (lorazepam, phenobarbital, and pentobarbital)-all within accepted dosing guidelines and a total daily PG exposure previously recognized to be safe. Hemodynamic measurements by bedside echocardiography during clinical toxicity are also reported. Clinicians should have a high index of suspicion for propylene glycol toxicity in patients treated with PG-containing medications even when the total PG exposure is lower than currently accepted limits.

Conflict of interest statement

The authors have no conflict of interests to disclose.

References

  1. J Pediatr Pharmacol Ther. 2015 Sep-Oct;20(5):367-72 - PubMed
  2. Pediatr Crit Care Med. 2009 Mar;10(2):256-9 - PubMed
  3. J Pediatr. 1978 Sep;93(3):515-6 - PubMed
  4. Crit Rev Toxicol. 2013 Apr;43(4):363-90 - PubMed
  5. Toxicol Sci. 1998 Dec;46(2):410-7 - PubMed
  6. Fundam Appl Toxicol. 1994 Jul;23(1):38-43 - PubMed
  7. Pharmacotherapy. 2006 Jan;26(1):23-33 - PubMed
  8. Lancet. 2003 Jan 25;361(9354):308 - PubMed
  9. J Intensive Care Med. 2008 May-Jun;23(3):184-94 - PubMed
  10. J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):277-82 - PubMed
  11. Semin Dial. 2007 May-Jun;20(3):217-9 - PubMed
  12. Intensive Care Med. 2002 Jan;28(1):81-4 - PubMed
  13. Am J Kidney Dis. 1997 Jul;30(1):134-9 - PubMed

Publication Types